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The first non-peptide vasopressin receptor antagonist (VRA)
was recently approved by the United States Food and Drug
Administration, and several others are now in late stages of
clinical development. Phase 3 trials indicate that these agents
predictably reduce urine osmolality, increase electrolyte-free
water excretion, and raise serum sodium concentration. They
are likely to become a mainstay of treatment of euvolemic
and hypervolemic hyponatremia. Although tachyphylaxis to
the hydro-osmotic effect of these agents does not appear to
occur, their use is accompanied by an increase in thirst, and
they do not always eliminate altogether the need for water
restriction during treatment of hyponatremia. Experience
with use of these agents for treatment of acute, severe,
life-threatening hyponatremia as well as chronic
hyponatremia is limited. Further studies are needed to
determine how they are best used in these situations, but the
risk of overly rapid correction of hyponatremia seems low.
Results of long-term trials to determine the ability of VRAs to
reduce morbidity or mortality in congestive heart failure or to
slow the progression of polycystic kidney disease are awaited
with great interest.
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The syndrome of inappropriate antidiuretic hormone secre-
tion (SIADH), congestive heart failure (CHF), and cirrhosis
are among many conditions associated with abnormal water
retention mediated by arginine vasopressin (AVP) release
inappropriate to plasma tonicity. Conventional therapies for
euvolemic or hypervolemic hyponatremia, including water
restriction, hypertonic saline, demeclocycline, and urea, all
have significant drawbacks. Selective vasopressin receptor
antagonists (VRAs) target the cause of abnormal water
retention by producing an increase in electrolyte-free water
excretion, or ‘aquaresis’, and could thus provide highly
specific therapy. Early studies suggest that, in addition to
their use as aquaretic agents, VRAs can potentially be used to
treat nephrogenic diabetes insipidus (NDI) owing to AVP
receptor mutations and may slow the progression of
polycystic kidney disease. The first VRA was recently
approved in the United States by the Food and Drug
Administration (FDA) for clinical use in patients with
euvolemic hyponatremia. This paper reviews the clinical
experience to date with non-peptide VRAs and discusses
their indications and potential future uses.
VASOPRESSIN RECEPTORS
AVP receptors are G-protein-coupled receptors. The three
subtypes differ in localization and signal transduction
mechanisms (Table 1). The vasopressin V1a receptor
(V1aR) is a Gq-coupled receptor that activates phospholipase
C and increases cytosolic free calcium. Its effect depends on
its location. Vasopressin V2 receptors (V2R), which are found
in vascular endothelium and the principal cells of the renal
collecting and connecting tubules, effect release of von
Willebrand factor and Factor 8 and mediate the hydro-
osmotic effect of vasopressin. The V2R is a 41 kDa protein of
371 residues with seven transmembrane domains. Binding of
AVP to the V2R activates the Gs adenylyl cyclase system,
increasing intracellular levels of cyclic 30,50-adenosine mono-
phosphate. The latter activates protein kinase A, which in
turn phosphorylates preformed aquaporin-2 (AQP2) water
channels localized in intracellular vesicles. Phosphorylation
promotes trafficking to the apical membrane, followed by
exocytic insertion of AQP2 vesicles into the cell membrane.
This is the limiting step in rendering the collecting duct water
permeable, as aquaporins 3 and 4 are constitutively present in
the basolateral membrane, although AVP also regulates the
former to some degree. AQP2 membrane insertion and
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transcription are reduced when AVP is chronically sup-
pressed, as in primary polydipsia. Diminished AVP effect, as
seen with hypercalcemia, hypokalemia, lithium, and NDI,
owing to V2R mutations, is also associated with reduced
AQP2 expression.1,2
VASOPRESSIN RECEPTOR ANTAGONISTS
Initial development efforts on VRAs during the 1970s
focused on peptide analogs derived from the selective V2R
agonist desmopressin. In the late 1980s, it seemed likely that
one such agent, a peptide with V2R antagonist effect in
animals, would be successfully developed for use in humans.
However, a phase 1 trial showed that the agent was a weak
V2R agonist in humans, and further development of peptide
antagonists was abandoned.3 Also, the peptide antagonists
had poor oral bioavailability, limiting their utility to
parenteral administration. Using a functional screening
strategy, non-peptide VRAs were subsequently identified. In
1993, Ohnishi et al4 reported the first use of an orally active,
non-peptide selective V2R antagonist to produce aquaresis in
healthy men.
ROLE OF VASOPRESSIN IN HYPONATREMIC STATES
Normally, when osmolality falls below its set point, plasma
AVP levels become undetectable, and an aquaresis results. In
SIADH, AVP release is not fully suppressed, despite
hypotonicity. In cirrhosis and CHF, impaired delivery of
solute to the diluting sites or even a diminished glomerular
filtration rate can impair maximal water-excretory capacity.
However, the persistence of AVP release owing to non-
osmotic stimuli is predominantly responsible for water
retention in these disorders. Under ordinary circumstances,
high-pressure baroreceptors in the ventricles, carotid sinuses,
and aortic arch acting through vagal afferents tonically
suppress release of AVP, renin, and catecholamines. Arterial
under-distension and baroreceptor unloading in CHF
inhibits this vagal tone. Consequently, AVP, catecholamine,
renin, angiotensin, and aldosterone levels are elevated in
patients with CHF.5,6 In cirrhosis, splanchnic vasodilatation
also leads to arterial underfilling with non-osmotic release of
AVP. Patients with cirrhosis and ascites or edema can be
classified according to whether they are able to excrete a
standardized water load. Along with water retention, ‘non-
excretors’ have worse liver disease, more sodium retention
and ascites, and higher AVP, renin, and aldosterone levels
than ‘excretors’ who handle a water load normally. Although
glomerular filtration rate is lower in non-excretors than
excretors, data from hypophysectomized animals with
cirrhosis or from cirrhotic animals treated with demeclo-
cycline show improved water excretion, and Brattleboro rats
with cirrhosis do not have a water excretion defect. Taken
together, these data suggest that non-osmotic release of AVP
is principally responsible for the abnormal water retention of
cirrhosis.7 Thus, patients with hyponatremia caused by
SIADH, CHF, and cirrhosis are all potential targets for
treatment with VRAs.
ORALLY ACTIVE NON-PEPTIDE VRAs IN DEVELOPMENT
Four non-peptide agents, all benzazepine or oxindole
derivatives, are now in various stages of clinical trials
(Figure 1 and Table 2). Conivaptan is a combined V1aR
and V2R antagonist; the others are selective V2R antagonists.
In December 2005, conivaptan was approved by the US FDA
for treatment of euvolemic hyponatremia. All agents of this
class are inhibitors of the cytochrome P450 3A4 system, but
conivaptan is the most potent. Although the drug is orally
active, to minimize the possibility of drug interactions, the
FDA has restricted its distribution to a parenteral form for
short-term in-hospital use only. The other three VRAs have
more limited CYP3A4 inhibitory activity and are being
developed for long-term oral use.
Molecular modeling of binding sites suggests that these
antagonists penetrate deeper into the transmembrane region
of the V2R than native AVP. They thereby prevent binding of
native hormone without themselves interacting with the H1
helix site that is critical for receptor-mediated G-protein
activation (Figure 2).8
Table 1 | Vasopressin receptor location and functions
Receptor Localization Functions
V1a Vascular smooth muscle Vasoconstriction, myocardial
hypertrophy
Platelets Platelet aggregation
Hepatocytes Glycogenolysis
Myometrium Uterine contraction
V1ba Anterior pituitary ACTH release
V2 Basolateral membrane
collecting tubule
Insertion of AQP2 water
channels into apical membrane,
induction of AQP2 synthesis
Vascular endothelium vWF and factor 8 release
Vascular smooth muscle Vasodilatation
ACTH, adrenocorticotropin hormone; AQP2, aquaporin-2.
aTermed V3 in some classification schemes.
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Figure 1 | Structure of the orally active VRAs. (a) Conivaptan,
a combined V1a/V2 antagonist. (b) Tolvaptan, a selective V2
antagonist.
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Lixivaptan
As the greatest published experience is with lixivaptan, results
using this agent will be discussed in detail. Based on
preliminary reports, results with the other agents should be
similar, although there are no published data to date in
patients using SR121463B.
In a phase 2 trial, six individuals with SIADH and five
individuals with cirrhosis received 50 or 100 mg lixivaptan or
placebo twice daily. In the SIADH patients, serum sodium
([Naþ ]) increased from 12675 to 13375.6 mmol/l after
48 h as urine flow rate increased from 0.8470.2 to
1.4670.4 ml/min and weight dropped by 1 kg. Urine
osmolality fell from 4147148 to 209755 mOsm/kg and
urine sodium excretion fell from 82722 to 45721 mmol/
24 h (all Po0.05 compared with placebo). Plasma renin,
aldosterone, and AVP levels and creatinine clearance were
unchanged. Serum uric acid rose from 2.970.8 to
3.771.1 mg/dl and blood urea nitrogen from 11.772.2 to
13.171.9 mg/dl (both Po0.05). The 7 mmol/l increase in
[Naþ ] appeared to be due to the combination of water
excretion (accounting for 5 mmol/l) and sodium retention
(accounting for 1.5 mmol/l). The rise in blood urea nitrogen
and uric acid along with the sodium retention were
consistent with correction of water overexpansion via
aquaresis. In the cirrhotic patients, [Naþ ] rose from
12672.9 to 13374.9 mmol/l over 72 h, uric acid was
unchanged, and blood urea nitrogen fell slightly from
17.874.5 to 1472.2 mg/dl. Urine sodium rose from
23718 to 65760 mmol/24 h. Potassium excretion also rose
slightly. Plasma AVP levels rose from 1.971.2 to 5.3 pg/ml
(all Po0.05), but renin and angiotensin levels did not
change. Taken together, these changes indicate that correction
of volume expansion in the SIADH patients was associated
with sodium retention. In contrast, the increase in sodium
and potassium excretion in the cirrhotic patients suggests
that distal sodium delivery increased as the hyponatremia was
corrected in these patients.9
In a dose-ranging trial, 27 patients with cirrhosis received
single doses of placebo or 25– 300 mg of lixivaptan. Dose-
related changes in urine flow rate, 14547858 versus
456874385 ml/24 h; net fluid balance, 3287811 versus
160871570 ml/24 h; [Naþ ], 1.271.0 versus 5.073.0 mmol/l;
minimum urine osmolality, 4897235 versus 78729 mOsm/
kg; and free water clearance, 0.3670.40 versus 6.7677.61
ml/min (all Po0.05, placebo versus 300 mg) were observed
along with a small but significant natriuresis.10
In a longer-term trial, 60 patients with cirrhosis received
50 or 100 mg lixivaptan or placebo twice daily, while
maintaining a 1 l/d fluid restriction. After 7 days, [Naþ ] in
the placebo-treated patients was unchanged but rose from
126.474.4 to 132.376.9 mmol/l in the 100 mg group. In the
placebo, 50, and 100 mg groups, 0, 27, and 50% of patients
normalized [Naþ ]. For responders, mean time to complete
response was 4.8 days in the 100 mg group and 5.7 days in the
50 mg group. Mean change in [Naþ ] per day was 0.170.2,
0.870.4, and 1.870.5 mmol/l per 24 h in the placebo, 50,
and 100 mg groups, respectively. A modest natriuresis also
occurred.11
In a separate study, 44 patients with a [Naþ ] below
130 mmol/l were given lixivaptan (25, 125, or 250 mg b.i.d.)
or placebo over 7 days, while maintained on a fluid
restriction. The diverse study population comprised indivi-
duals with cirrhosis, CHF, and SIADH. The changes in
[Naþ ] and urine osmolality over the course of the study are
shown in Figure 3. The [Naþ ] rose in a dose-dependent
fashion, but appeared to reach a plateau, in part because 12
Table 2 | Non-peptide vasopressin antagonists currently
under commercial development
Compound Receptor Route Manufacturer
Conivaptan (YM-087) V1a+V2 i.v. Astellas (Tokyo, Japan)
Lixivaptan (VPA-985) V2 Oral CardioKine (Philadelphia,
PA, USA)
Tolvaptan (OPC-41061) V2 Oral Otsuka (Tokyo, Japan)
SR-121463 V2 Oral Sanofi-Aventis (Paris, France)
i.v., intravenous.
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Figure 2 | V2 receptor shown as a ribbon diagram. For the receptor
(green), loops labeled ‘e’ are extracellular and loops labeled ‘i’ are
intracellular. Models of arginine vasopressin (AVP, multicolored) and a
V2 receptor antagonist (OPC21268, dark blue) are shown at the sites
where they would dock were the other not present. Binding sites are
distinct with partial overlap. The antagonist, which lodges deeper in
the receptor than AVP, prevents AVP docking but does not interact
with the receptor’s active site in the H1 helix. The figure was
graciously provided by Dr Menachem Shoham and modified with
permission from Macion-Dazard et al.8
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of 44 subjects dropped out (half because of postural
hypotension) and in part because of the complex rules that
called for withholding medication and liberalizing fluid
intake if the [Naþ ] increased more than 8 mmol/l from the
previous measurement or if the [Naþ ] rose above 142 mmol/
l. More patients in the higher dosage groups required
medication holds, including half the patients in the highest
dosage group. Free water clearance was higher and urine
osmolality lower than placebo in the two higher dosage
groups, but again the results were blunted because of
medication stop rules. As measured by visual analog scale,
thirst increased in all groups receiving active medication, but
reached statistical significance versus baseline or placebo only
in the highest dosage group. Plasma AVP levels on the final
day of the study were higher than placebo in the two highest
dosage groups only; separate data were not provided for
SIADH and cirrhosis patients. Plasma norepinephrine, renin,
and aldosterone levels were unchanged. This study makes it
clear that care will be needed in selecting the long-term dose
of a VRA if excessive aquaresis is to be avoided.12
Tolvaptan
The original non-peptide V2R antagonist, OPC-31260,
demonstrated the anticipated effect on urinary concentration
and water excretion in studies in normal individuals and
patients with cirrhosis or SIADH.4,13–15 Subsequent com-
mercial development by Otsuka has focused on the more
potent compound OPC-41061, tolvaptan, which has been
studied primarily in individuals with CHF. In one study, 254
patients with NYHA class 2 or 3 CHF were maintained on
stable doses of furosemide and randomized to receive
tolvaptan 30, 45, or 60 mg or placebo once daily for 25 days.
Patients were not fluid restricted. After 24 h, the tolvaptan
patients lost 0.8 kg, and the placebo patients gained 0.32 kg.
This difference was significant, similar in all dosage groups,
and persisted with no additional weight loss over the study
period. Urine osmolality at study conclusion was
52.057144.96 mOsm/kg below baseline in the tolvaptan
60 mg group (Po0.05) and 163.77202.53 mOsm/kg above
baseline in the placebo group (NS). The 24-h sodium
excretion in the first day was approximately 50% higher in
the treated groups (e.g., 355 mmol/24 for the tolvaptan 60 mg
group, 193.7 mmol/l for the placebo group, Po0.05). In the
tolvaptan group, the [Naþ ] increased approximately
3 mmol/l on day 1, but was unchanged in the placebo group.
In the initially normonatremic tolvaptan patients, the [Naþ ]
returned to baseline by the end of the study. Among the 28%
of enrollees who were hyponatremic at study initiation, there
was a greater increase, and [Naþ ] concentrations remained
within the normal range through study termination in twice
as many initially hyponatremic tolvaptan-treated individuals
(82%) compared to placebo. Hypernatremia developed in 5,
6, 11, and 13% of subjects in the placebo, 30, 45, and 60 mg
groups, respectively. Relative to the placebo group, edema
scores improved, thirst increased, and vasopressin levels
trended upward in the active treatment group. Requisite
balance data were not obtained, but it is reasonable to assume
that [Naþ ] levels drifted back to baseline despite lower urine
osmolalities because water intake increased in the treatment
groups. In summary, tolvaptan had a modest effect on weight
and led to a correction of hyponatremia that was sustained
for 25 days without significant hypernatremia.16
In a companion study, 319 patients with ejection fraction
o40%, who required hospitalization for a CHF exacerbation,
were randomized to receive placebo or 30, 60, or 90 mg
tolvaptan. The primary end point was in-hospital weight loss,
which was greater in the tolvaptan group. The weight change,
pattern of [Naþ ] change, and rate of normalization of [Naþ ]
in hyponatremic patients in this study were similar to those
in the previous study. Additional primary end points were
worsening CHF or unscheduled visits for CHF within 60
days. Although these were not different among the treatment
groups, in post-hoc analysis, 60-day mortality was signifi-
cantly lower in tolvaptan-treated patients with renal dysfunc-
tion or severe congestion at baseline.17 This study was not
powered to determine whether tolvaptan might reduce
cardiovascular mortality. However, a large-scale, multicenter
phase 3 trial comparing tolvaptan 30 mg daily to placebo is
currently underway to answer this important question.18
In a more recent trial with tolvaptan, SALT2 (sodium
assessment with increasing levels of tolvaptan in hypo-
natremia), approximately 200 hyponatremic patients received
15–60 mg tolvaptan in a stepwise fashion for 30 days. Similar
to the lixivaptan trials, significantly greater increases in serum
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Figure 3 | Serum and urine response to lixivaptan. (a) Serum
sodium and (b) urine osmolality during a 7-day course of placebo (D),
or lixivaptan 25 mg b.i.d. (K), 125 mg b.i.d. (’), or 250 mg b.i.d. (m).
*Po0.05 versus placebo; **Po0.01 versus placebo; #Po0.05 versus
25 mg b.i.d.; zPo0.05 versus 125 mg b.i.d. Reproduced with
permission from Wong et al.12
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[Naþ ] occurred in the tolvaptan-treated patients compared to
placebo, although 25% of the patients dropped out, and
resistance (defined as a failure of [Naþ ] to rise by 5 mmol/l)
occurred in 37% of cirrhosis, 17% of CHF, and 11% of SIADH
patients (Gross P, presented at the American Society of
Nephrology Annual Meeting, Philadelphia, November 2005).
Conivaptan
Conivaptan is a mixed V1aR and V2R antagonist. Use of a
combined antagonist has the theoretical advantage of
mitigating any unopposed V1aR activation, which could be
particularly desirable in patients with CHF. In a study of 142
patients with NYHA class 3 or 4 CHF who were randomized
to receive placebo or a single intravenous dose of conivaptan,
10, 20, or 40 mg, active drug at the 40 mg dose reduced
pulmonary capillary wedge pressure by 4.670.7 mm Hg
compared with 2.670.7 mm Hg for placebo (Po0.05). Right
atrial pressure was also significantly lower in the treatment
groups. These effects were sustained for 12 h after drug
dosing. Urine osmolality fell and urine output rose in the
treatment groups, but cardiac index, mean arterial pressure,
systemic vascular resistance, pulmonary vascular resistance,
and heart rate were not significantly different. [Naþ ] did not
change significantly, although a 1.5 mmol/l rise was observed
in the 40 mg group along with a small and significant rise in
AVP level.19 Whether the prompt reduction in pulmonary
capillary wedge pressure was entirely due to the V2R-
mediated aquaresis or also involved vasorelaxation owing to
V1aR antagonism cannot be ascertained.
Results of a phase 3 clinical trial in patients with SIADH
or CHF and hyponatremia randomized to receive placebo or
a 20 mg bolus of conivaptan followed by continuous
intravenous infusion of 40 or 80 mg conivaptan per day for
4 days along with modest water restriction showed a mean
increase in [Naþ ] of 2.070.8 mmol/l in the placebo group,
6.870.8 mmol/l in the 40 mg, and 9.070.8 mmol/l in the
80 mg group (Po0.05 for both versus placebo). Of note was
the more rapid correction of [Naþ ] in the first 24 h than has
been reported to date with the oral V2R antagonists, perhaps
reflecting enhanced bioavailability of the intravenous pre-
paration; median time to a 4 mmol/l increase in [Naþ ] was
23.7 h in the 40 mg group and 23.4 h in the 80 mg group.
[Naþ ] increased by 6 mmol/l or more in 20.7, 69, and 88.5%
of individuals in the three groups, respectively. Overly rapid
correction was rarely observed and was not associated with
clinical consequences. The only potentially concerning side
effect was local irritation at the infusion site (Verbalis JG et al.
J Am Soc Nephrol 2004; 15: 356A). Oral dosing produced
similar changes in [Naþ ] (Verbalis JG et al. Endocrine Society
87th Annual Meeting, San Diego, 2004 (abstract P3–P183)).
Conivaptan, 20 mg orally twice daily, along with 1.5 l fluid
restriction was used successfully to maintain a normal [Naþ ]
in two patients with chronic hyponatremia owing to SIADH.
Fluid restriction alone was unsuccessful, but [Naþ ] was
maintained within the normal range during the 90-day
period of combined therapy (Figure 4).20 Although effective,
the oral preparation is no longer being developed for clinical
use because of concerns during long-term use about
interactions with other drugs metabolized by the CYP3A4
pathway.
POTENTIAL USES FOR V2R OR COMBINED V1aRþV2R
ANTAGONISTS
Hyponatremia
V2R antagonists will become a mainstay of treatment for
euvolemic (i.e., SIADH, postoperative hyponatremia) and
hypervolemic hyponatremia (i.e., CHF and cirrhosis). As
detailed above, these agents predictably cause an aquaresis
leading to increased [Naþ ] in the majority of patients with
hyponatremia due to SIADH, CHF, and cirrhosis. Although
the initial FDA approval for conivaptan was only for the
indication of euvolemic hyponatremia, increased exposure of
larger numbers of patients with CHF to VRAs should
eventually lead to approval for the indication of hyper-
volemic hyponatremia. The optimum use of VRAs has not
yet been determined, but some predictions can be made with
reasonable certainty. For hyponatremia in hospitalized
patients, who are unable to take medication orally or for
those in whom a more rapid correction of hyponatremia is
desired, conivaptan will likely be the preferred agent. Phase 3
studies show that it reliably raises [Naþ ] over the short term
beginning as early as 1–2 h after administration, and permits
normalization of [Naþ ] in most hyponatremic patients over
a 4-day course of treatment (Verbalis JG et al. J Am Soc
Nephrol 2004; 15: 356A; Verbalis JG et al. Endocrine Society
87th Annual Meeting, San Diego, 2004, Abstract P3–P183).
Selective V2R antagonists such as lixivaptan, tolvaptan, or
SR121463B will likely be useful in patients for whom oral
therapy is suitable and for more chronic forms of
hyponatremia.
Despite the attractiveness of using a pure aquaretic agent
to correct life-threatening hyponatremia, insufficient data are
available from clinical trials to know if sufficiently rapid
correction can be achieved in patients with acute, severe
hyponatremia without the use of hypertonic saline. Theore-
tically, both could be used initially; the hypertonic saline
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could be stopped after the [Naþ ] increases a few mmol/l,
with the remainder of the first day correction to be
accomplished with the water diuresis. The two agents may
be complementary in that the hypertonic saline infusion
would cause sufficient expansion to mitigate any volume
depletion resulting from the aquaresis.
Most studies employing these agents to treat hyponatre-
mia have been of limited duration, generally only 1–7 days.
However, sufficient data from longer-term studies exist to
expect that the agents will likely prove to be highly useful in
chronic hyponatremia, owing to SIADH, cirrhosis, and CHF.
Although the effect of VRAs on plasma AVP levels is variable,
it bears emphasis that the VRAs often increase thirst even in
hyponatremic patients and, unless restricted, water intake
generally increases as well. As an example of this, in the initial
tolvaptan CHF study, the [Naþ ] rose only during the first
day, despite a persistently dilute urine.16 Thus, use of VRAs
will mitigate, but in many cases not altogether eliminate the
need for fluid restriction.12,20
Safety issues must also be considered carefully with any
new class of agents. The possibility of overcorrection has been
of significant concern in all of the VRA clinical trials, but to
date osmotic demyelination has not been reported with any
agent. Nonetheless, it is anticipated that the agents will need
to be used judiciously if correction of the [Naþ ] at a rate
faster than 8–12 mmol/l/24 h is to be avoided.21 Because of
their o12 h half-life, all of the agents will require daily or
continuous dosing to maintain activity, so it will be possible
to limit the [Naþ ] rise by stopping the drug or reducing the
dosage. If necessary, hypotonic fluid can be infused to
abrogate the rise in [Naþ ] until the aquaresis abates. These
safeguards should be sufficient to protect against overly rapid
correction if [Naþ ] levels are monitored frequently during
the course of active treatment. A second major concern is to
avoid using VRAs in cases of hypovolemic hyponatremia,
where an aquaresis would aggravate the underlying volume
contraction and potentially cause hypotension. This can be
avoided by careful attention to the appropriate differential
diagnosis among the different subtypes of hyponatremia.22 A
third concern is the production of hypotension, particularly
with antagonists having activity at V1aR. This has not been
reported as a significant adverse event in the conivaptan
clinical trials to date, but, because of the potential for
splanchnic vasodilatation that could produce hypotension or
promote variceal bleeding, effects of conivaptan have not
been carefully examined in patients with cirrhosis. The
potential for serious drug interactions via interference with
CYP3A4 metabolism of other drugs must be recognized. This
will likely not be of concern with short-term use of VRAs
such as conivaptan, but may cause problems during long-
term therapy, requiring appropriate monitoring. Finally,
whether there will be any adverse effect of V2R inhibition
in vascular endothelium is unknown. Bleeding complications
have not been reported to date, but surveillance will be
needed now that a V2R antagonist will soon be in general
use.
Congestive heart failure
It is well established that the neurohormonal activation
characteristic of CHF, including increased renin, angiotensin,
aldosterone, and catecholamines, contributes to progression
of CHF.23 Abundant evidence from large-scale clinical trials
attests to the reduction in cardiovascular mortality that
accrues from treatment with angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, b-adrenergic block-
ers, and aldosterone antagonists.24 Subgroup analysis sug-
gests that cardiovascular mortality may be reduced by the
selective V2R antagonist tolvaptan in the higher risk group
with kidney function impairment or severe congestive
findings.17 As the V1aR is responsible for the pressor and
mitogenic effects of AVP and as plasma AVP levels rise in
some settings during V2R blockade, it is also possible that
long-term isolated V2R blockade could prove deleterious to
patients with CHF. A well-powered study to determine
whether selective V2R antagonist therapy will prove as
beneficial as other inhibitors of the CHF neurohormonal
cascade is ongoing,18 although it will not establish whether
long-term combined V1a and V2R antagonism might be
superior. Until such studies have been completed and an FDA
indication is granted for use in CHF with or without
accompanying hyponatremia, VRAs are not recommended in
patients with CHF.
Cirrhosis
Although the hyponatremia of cirrhosis is analogous to that
of CHF in many respects, the presence of portal hypertension
in these patients presents additional concerns, namely, that
V1aR blockade may produce hypotension and variceal
bleeding owing to antagonism of AVP pressor effects in this
vascular bed. Consequently, at the present time, only selective
V2R antagonists can be recommended for these patients. The
lixivaptan and tolvaptan trials provide conflicting data as to
whether cirrhotic patients will be as responsive as patients
with other causes of hyponatremia.
Polycystic kidney disease
Cyclic 30,50-adenosine monophosphate-dependent genes pro-
mote fluid secretion into developing renal cysts and increase
cell proliferation.25 Polycystin-1 may directly inhibit adenyl
cyclase, and polycystin-2 acts to increase intracellular calcium,
which in turn inhibits adenyl cyclase and increases the activity
of collecting duct phosphodiesterases. Thus, polycystin
defects may promote cyst development because they lead to
increases in intracellular cyclic 30,50-adenosine monopho-
sphate.26 The second messenger for AVP acting at the V2R is
cyclic 30,50-adenosine monophosphate. Studies in several
animal models of polycystic kidney disease have shown a
reduction in kidney size and cyst volume after treatment with
the V2R antagonist OPC-31260.26 A phase 2 dose-ranging
and tolerability trial of tolvaptan in patients with autosomal
dominant polycystic kidney disease is now ongoing, and the
results of a full-scale therapeutic trial would be of great
interest (Chapman A et al. J Am Soc Nephrol 2005; 16: 68A).
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Nephrogenic diabetes insipidus
Congenital NDI may result from V2R or AQP2 mutations.
The V2R mutations include type 1 mutations that prevent
AVP binding, type 2 mutations that cause misfolding and
interfere with trafficking of receptor from endoplasmic
reticulum to cell membrane, and type 3 mutations that lead
to transcription of unstable mRNA. Exogenously adminis-
tered V2R antagonists can bind to misfolded intracellular
V2R, and improve transport of V2R to the cell membrane.27
Clinical studies in patients with X-linked NDI showed
that the selective V1aR antagonist relcovaptan (SR49059,
Sanofi-Aventis) significantly increased urine osmolality
(98722–170752 mOsm/kg) and decreased 24-h urine flow
(11.972.3–8.272.0 l).28 Although the effect was modest,
these results suggest that V1aR and/or V2R antagonists might
serve as molecular chaperones to mitigate misfolding defects
in selected patients with type 2 NDI.
CONCLUSIONS
Specific VRAs for clinical use have been long awaited. The
recent FDA approval of conivaptan ushers in a new era in the
treatment of hyponatremia. Use in patients with euvolemic
hyponatremia is now permitted; additional clinical data to
confirm safety of VRAs in CHF and cirrhosis should soon
allow their use in hypervolemic hyponatremia. Most studies
in hyponatremic patients to date have only been short term.
Hence, the most appropriate way to use these agents, their
long-term response rates, how important the role of water
restriction will remain during chronic use, and whether
correction of chronic hyponatremia will result in improved
cognitive function, quality of life, or functional status remain
important unknowns. Similarly, whether the effect of VRAs
will be predictable enough to make them useful in acute,
symptomatic hyponatremia also remains uncertain. VRAs
may prove to be beneficial as well for effects that are not
directly related to correction of hypotonicity. These include
potential roles to enhance the cocktail of neurohumoral
blockade employed to reduce mortality in CHF, to slow the
progression of cyst growth in polycystic kidney disease, and
to ameliorate polyuria in some forms of congenital NDI. All
of these as well as presently unrecognized uses will await the
results from both large-scale outcome trials and focused
small-scale trials with VRAs.
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